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ABSTRACT 
 
 
The Investigation of Controlled Release Microchips, Nanoparticles, and siRNA for Gene 
Delivery in Tissue Engineering Applications. (December 2008) 
Christina Chern, B.S., Carnegie Mellon University 
Chair of Advisory Committee: Dr. Mariah Hahn 
 
 The study of drug delivery for the treatment of illnesses and injuries is an 
important area of pharmaceutical technology.  A relatively new area of drug delivery 
being explored is gene therapy, which utilizes the idea that genes can be used as an 
alternative treatment.  The exploration of gene delivery brought major advancements in 
the treatment of cancers and tumors as well as many challenges.  In this study, the 
challenges of maintaining a stable vehicle for delivery, delivering genes into the cells, 
and the efficacy of the gene delivery vehicle were explored.   
Seven co-polymers of 12% (w/v) poly (D, L-lactic glycolide) (PDLG) were used 
to find a biodegradable polymer composition as an implant that temporarily controls the 
delivery of the genes.  Of the formulations tested, 65/35 DL 3A and 50/50 DLG 4A were 
observed to show degradation time frames that best fit our purposes.   
Also, nanoparticles have been used to aid in the targeting of drugs to desired cells 
in delivery.  One drawback of using nanoparticles is the potential toxic side effects they 
might cause.  Zinc oxide nanoparticles coated with poly (vinyl pyrrolidone) (PVP) used 
as drug carriers were observed to have an effect on cell viability in previous studies.  The 
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cytotoxic effects of ZnO nanoparticles and PVP have on NIH 3T3 mouse fibroblast cells 
were investigated to see if there is a direct correlation between the level of PVP and zinc 
nanoparticles to the amount of cell death.  It was found that an increase in concentration 
of ZnO nanoparticles correlates to a decrease in viability of the cells.  It was also noted 
that the method of cell death is likely to be apoptosis.   
To confirm the efficacy of gene therapy through transfection, the transfection of 
the serum response factor (SRF) gene plasmid DNA and short interfering RNA (siRNA) 
were investigated.  The efficiency of the transfection method were tested for both two-
dimensional and three-dimensional transfection of the SRF plasmid and siRNA.  
Experiments with two-dimensional transfection of the SRF plasmid and siRNA were 
successful, and transfer of the gene in the three-dimensional environment was observed 
with promising results with the siRNA. 
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1. INTRODUCTION: DRUG DELIVERY 
 
1.1 The Importance of Drug Delivery 
 Drug delivery is an important aspect of pharmaceutical technology and tissue 
engineering in treating illnesses and injuries with substances that can potentially improve 
the conditions of patients.  Tissue engineering involves the development of new 
materials that encourage cell infiltration and proliferation to treat or replace damaged 
tissue.  Controlled, targeted release of drugs brings therapeutic effects for the engineered 
tissues in applications such as wound healing, anti-inflammatory treatment near 
implants, and anti-tumor therapies.  Drugs can be delivered in many forms such as 
solids, liquids, and aerosols.  They can also be delivered in conjunction with a drug 
carrier to assure targeted drug delivery effectiveness by preventing the drug from being 
absorbed or degraded on its way to the target site or by directing the drug to its target 
site.  Effectively delivering the drug to the target site and have the drug maintain its 
activity is harder than it seems as the human body has many natural barriers that prevent 
foreign drug molecules from penetrating and passing through such as the blood-brain 
barrier and the stratum corneum of the skin1, 2.  Phagocytes may also take up the drugs 
and deliver it to undesired destinations in the body3.   
 Gene therapy utilizes the concept that a gene can be inserted into the cells of 
patients through transfection to either replace or deactivates a mutated or damaged gene  
 
________________ 
This thesis follows the style of Journal of the American Chemical Society. 
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that is causing the disease.  The gene can also be a gene that was not present before that 
is introduced to help fight the disease.  This method is attractive for diseases with no 
current cures, such as hereditary disorders, cancers, and certain viral infections4.  In 
theory, gene therapy can be done simply though intravenous injection of siRNA or 
plasmid DNA at the site.  The cell takes the gene into the nucleus through endocytosis as 
shown in Figure 1 with a lipid-based non-viral vector5.   
 
 
Figure 1. Schematic of How Gene Transfer Takes Place in a Cell6. 
 
1.2 Current Methods and Approaches  
Drug delivery methods currently used include injections, trans-dermal diffusion, 
ingestion, inhalation, and timed release implantation7.  The method of delivery depends 
on the molecule size, location of the target site, and the purpose of the drug.  The 
advantages of trans-dermal diffusion are that it provides an alternative method of drug 
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delivery when other methods are not ideal, the skin provides a relatively large and 
readily accessible surface area, and a path-like device to the skin surface is non-invasive 
but at the same time it allows continuous intervention.  A major drawback of trans-
dermal diffusion is that bigger molecules cannot be absorbed through the skin and will 
have to be delivered via another method since they will not be able to get through the 
tortuous stratum corneum layer of the skin.  Proteins, peptides, and oligonucleotides are 
also difficult to deliver through trans-dermal diffusion due to their half-lives, but they 
are still desirable sources of drugs due to their highly specific and potent nature 
compared to other forms of drugs2.   
Injection is also an effective method if possible, but there is pain involved for the 
patient as well as problems with maintaining a therapeutic effect for drugs with short 
half-lives and the fact that it is an invasive procedure.  Almost all types of drugs can be 
administered through injection such as nanoparticles, proteins, antibodies, and viral 
particles.     
Inhalation utilizes the large surface area of the alveoli of the lungs that can 
absorb drugs, which increases the speed of the uptake of drugs, the relatively thin 
epithelial barrier, extensive vascularization and low proteolytic activity in the alveolar 
space of the lungs.  Smaller molecules can also be delivered through this method due to 
the thin epithelial barrier that it has to overcome to be absorbed into the system.  Aerosol 
drug delivery is a non-invasive delivery method that also prevents the potential for poor 
absorption and/or high metabolism in the gastrointestinal tract and first-pass losses in the 
liver of patients that are seen in oral delivery methods3.    
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 Timed-release implantations have also been used in many applications such as 
for the delivery of parathyroid hormone (PTH) for patients with osteoporosis and stent 
implants.  In this study, gene delivery for timed-release implantation applications was 
explored.     
These different types of drug delivery methods are desirable as long as certain 
criteria are met in order for them to be suitable drug delivery systems.  The material used 
as the carrier should be biocompatible (i.e., no toxic byproducts should form when it is 
inside the body), limited premature release of the drug, cell type or tissue specificity and 
site directing ability, and controlled release of drug molecules with a proper rate of 
release to achieve an effective local concentration.  These requirements should be met as 
close as possible to reduce inflammatory response to the foreign particles or systems as 
well as reduced efficiency of the drug that is applied8.  
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2. GENE DELIVERY IN TISSUE ENGINEERING APPLICATIONS 
2.1 Controlled Release Microchips 
 The effectiveness of the drug is affected by how the drug is released into the 
system.  Immediate release drug delivery is not beneficial to patients with certain 
diseases or disorders such as asthma, arthritis, and gastric ulcer due to the nature of the 
human body following a rhythmic pattern, so treatments at certain times are more 
effective than if the drug dosage was administered all at once.  Pulsatile drug 
administration allows for controlled and predetermined application of drugs over a 
period of time and helps maintain a therapeutically effective level of the drug within the 
patient’s system.  Pulsatile drug release is another area of research that has been gaining 
attention due to the different materials that can be used to achieve this effect when 
administered.  These delivery systems are either stimulus-induced or self-regulated 
release systems.  Stimulus-induced delivery systems are stimulated by temperature, pH, 
light, enzyme or electric and magnetic fields.  There have been promising results from 
stimulus-induced delivery systems, but they are usually made of non-biodegradable 
material in which the host body will elicit an immune rejection towards the implant.  
Self-regulated delivery systems are usually erodible or biodegradable polymers with an 
encapsulated drug.  The release times are often times varied by the thickness and 
structure of the encapsulation material.  While this delivery system utilizes 
biodegradable and biocompatible materials as the vehicle of delivery, it is difficult to 
fabricate the different thicknesses for different release times on a small scale, which 
leads to inconsistent results seen in several reports9.  Doctors use the knowledge of the 
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behavior of the drug and its purpose to determine dosages, how often to administer the 
drug, and how the drug should be delivered to the patient.   
An example of a timed-release implantation system would be stent implants with 
a coated layer of drugs.  Stent implants save the lives of many patients with 
cardiovascular diseases, but the implant poses a problem as a foreign object in the body.  
It is also associated with an excessive proliferation of vascular smooth muscle cells, 
extracellular matrix synthesis, thrombosis, and chronic inflammation.  One solution to 
these problems is to fabricate the stent with a coated polymeric layer in which 
therapeutic agents are released gradually after implantation to alleviate the biological 
responses10.  This method of drug delivery has also been used in other applications for 
insulin delivery or parathyroid hormone (PTH) delivery where it has been shown to 
stimulate bone formation through improving bone micro-architecture, mineral density, 
and strength for patients with osteoporosis11.  In addition to using pulsatile delivery 
systems for timed release of drugs over an extensive period of time, the technology can 
also be used for other applications where the drug needs to be applied locally, is not 
easily absorbed or has an extensive first pass metabolism.   
A self-regulated release drug delivery system example would be the microchip 
multi-dose drug release device Grayson et al12 developed, which is explored in this work 
for its application as a stable means of delivering genes as drugs.  For this device, 
degradable polymers are used as the cover on the reservoir openings as well as the 
microchip material as seen in Figure 2.   
7 
 
 
Figure 2.  Schematic of the Self-Regulated Microchip Multi-Dose Device12. 
 
 
 
The premise of the design is that each reservoir is sealed with polymers with 
different properties for different degradation times12.  These varying properties could be 
the molecular mass, material, thickness or composition of the membrane.  In this work, 
the composition of the PDLG copolymer will be varied to identify formulations that 
show a degradation time of around two weeks for our purposes.  The use of an 
implantable biodegradable device will allow the release of the gene into body over a 
period of time, which saves the patient from having to visit the hospital regularly for 
injections, surgeries, and hospital visits for drug administrations. 
2.1.1 Materials 
In this work, the degradation times of the co-polymers with compositions of 12% 
(w/v) of each 65/35 DL 3A, 50/50 DLG 2.5A, 50/50 DLG 4A, 50/50 DLG 5A, 75/25 
DLG 1A, 75/25 DLG 2A, and 85/15 DLG 1A, where the convention of nomenclature is 
based on the percentage of each lactide and glycolide concentration in the polymer and 
the number following the co-polymer acronym denotes the chain length, were observed.  
The polymers were dissolved in 99% 1, 1, 1, 3, 3, 3 – Hexafluoro-2-propanol and were 
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monitored through microscopy to identify polymer compositions that have an 
approximate two week degradation time frame.  The polymers degraded through 
hydrolysis from the water present in the media and likewise in the body.  Polymer 
degradation is largely dependent on its rheology and morphology.  The degradation time 
of a polymer depends on its hydrophilicity, glass transition temperature (Tg), 
crystallinity, molecular weight, and porosity.  The polymer used in this study for the 
timed release experiment is PDLG, which is a co-polymer of lactide and glygolide.  
Lactide and glycolide are similar in structure with the exception of a methyl side group 
on lactide (Figure 3), which makes the polymer less crystalline and more amorphous13.  
Polyglycolide has a Tg of between 35-40 oC and polylactide has a Tg of between 50-80 
oC 14, 15 and polylactide has a higher molecular weight due to the extra pendant group.    
 
 
 
 
Figure 3. Schematic of the Degradation of PDLG16. 
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By looking at the polymer structure and properties it can be theorized that the 
polymer with a higher lactide content and longer chain will have a longer degradation 
time due to the fact that it has a higher Tg and is less hydrophilic even though it is less 
crystalline in structure13.  We hypothesized that 50/50 DLG 5A and 50/50 DLG 4A will 
be the formulations that best fits our experiment purposes due to the higher 
concentration of lactide and longer chain of the polymers.   
2.1.2 Methods 
2.1.2.1 Making of Microchips 
Microchips for pulsatile drug release were created by using a Teflon mold with 
four peaks.  The microchips were made with 1g of 100 DL 4.5A (Lakeshore 
Biomaterials, Birmingham, AL).  The dry polymer pellets were melted on a Carver press 
at 180 oF on top of a flat Teflon piece and approximately 13,500 lbs of force was applied 
to the melted polymer with the Teflon mold on top to make the indentation of reservoirs 
to hold the drugs.  The sandwiched piece was cooled with running water and pulled apart 
from the Teflon pieces.  It was then sanded down on both sides by hand for a smooth, 
flat surface with a 400 grit superfine sandpaper (Norton, Sanborn, NY). The microchips 
were sanded down until the opening was approximately 0.75 mm in diameter. 
2.1.2.2 Making of Polymer Capsules     
Dry polymer pellets of 65/35 DL 3A, 50/50 DLG 2.5A, 50/50 DLG 4A, 50/50 
DLG 5A, 75/25 DLG 1A, 75/25 DLG 2A, and 85/15 DLG 1A (Lakeshore Biomaterials, 
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Birmingham, AL) were dissolved in 99% 1, 1, 1, 3, 3, 3 – Hexafluoro-2-propanol 
(Sigma-Aldrich, St. Louis, MO) solution with a 12% (w/v) concentration.   A table of the 
properties of the polymers is presented16:  
                    Table 1. Polymer Properties  
Polymer Name 
Intrinsic 
Viscosity MW (kDa) 
6535 DL 3A 0.37 45 
5050 DLG 2.5A 0.25 28 
5050 DLG 4A 0.39  
5050 DLG 5A 0.52  
7525 DLG 1A 0.12 6.6 
7525 DL PLG 2A 0.17 14 
8515 DLG 1A 0.14 8.1 
 
The desired thickness of the polymer capsule is 150 µm, which through 
calculations yields about 2.5 µL of polymer solution each well.  The microchips were 
dried overnight in an open hood and placed in a vacuum oven overnight with 
approximately 27 inHg of pressure in order to remove the solvent from the polymer 
capsules.  The microchips were initially sealed by applying tape to the back side.  Later 
experiments was sealed by using a piece of 0.75g of melted 100 DL 4.5A as the backing 
that was further sealed with 30% (w/v) 100 DL 4.5A dissolved in 99% 1, 1, 1, 3, 3, 3 – 
Hexafluoro-2-propanol.  The disc was dried overnight in an open hood and placed in a 
vacuum oven overnight with approximately 27 inHg of pressure.  The microchips were 
then sterilized through one hour of exposure to UV light in the hood on each side and 
placed in a tweleve well plate (B. D. Falcon, Franklin Lakes, NJ) with cell culture media 
(DMEM + 10% DFBS + PS).   
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2.1.2.3 Monitoring Degradation 
The microchips were placed in two mL of phosphate buffered saline (PBS) 
(Hyclone, Logan, UT) or culture media and incubated at 37˚C/5% CO2.  The PBS or 
culture media was changed every two days due to possible side effects the acidic 
degradation products created through hydrolysis might have on the non-degraded 
polymers16.  The openings of the wells were observed daily with a microscope to 
determine if the wells were opening.   
2.1.3 Results 
Initial testing of the polymer compositions showed that when the polymers were 
incubated in PBS, 50/50 DLG 5A was observed to be the only formulation that have a 
degradation time of around two weeks compared to the others, which was hypothesized 
earlier.  However, when the polymers were incubated in cell culture media it was 
observed that 50/50 DLG 4A and 65/35 DL 3A were the two formulations that appear to 
have a degradation time of around two weeks.  Figure 4 shows pictures of representative 
polymer capsule coverings degrading through time.     
 
       
Figure 4. Time Lapse of Degrading Polymer Coverings. 
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The observations of the degradation times of the two polymer formulations were 
then repeated to confirm the observations.  New discs were made of 12% 65/35 DL 3A 
and 12% 50/50 DLG 4A with 100 DL 4.5A as the backing and sealed with 30% 100/0 
DL 4.5A dissolved in 99% 1, 1, 1, 3, 3, 3 – Hexafluoro-2-propanol.  It was observed that 
12% 65/35 DL 3A degraded significantly around two weeks, but 12% 50/50 DLG 4A 
appears to have released in the first four days.  Fresh materials were used for the third 
time where 12% 65/35 DL 3A, 12% 50/50 DLG 4A, and 12% 50/50 DLG 5A were 
made in the same manner as the previous experiment.  50/50 DLG 5A was included 
because it should have the longest degradation time due to its polymer properties, and 
we wanted to see if a fresh batch will yield different results from before.  12% 50/50 
DLG 4A was observed to have opened wells after nine days whereas 12% 65/35 DL 3A 
still exhibited a two week degradation time frame.  12% 50/50 DLG 5A was observed to 
have degraded within a week.   
 
2.2 The Use of Nanoparticles in Drug Delivery 
Nanoparticles are defined as particles less than 100 nm in diameter.  It was 
observed that the properties of known materials changed by decreasing the size to the 
nanoscale range, thus, creating opportunities for more efficient and versatile uses of 
these materials17.  Various methods of drug delivery have been employed throughout the 
past in pharmaceutical technology including the use of colloidal delivery systems with 
liposomes, micelles, and nanoparticles.  These systems arose because of the need of a 
drug carrier that would prevent the encapsulated drug from being degraded or provide a 
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way to target the drug to a specific site in order to limit contact with the surrounding 
tissue with the drug and maximizing the amount of drug delivered to the desired site.   
Nanoparticles are beneficial in drug delivery due to the size of the drugs that can 
be used as well as their flexibility and convenience in methods of formulation and 
delivery.  They do not settle easily, dissolve quickly, and have a high affinity for 
adherence to biological surfaces.  These particles can be administered through a variety 
of methods such as oral, pulmonary, parenteral, intraocular or transdermal drug delivery 
systems depending on the effectiveness of each for the target site.  Usually, site-specific 
delivery to target organs is administered through parenteral injection and delivery to the 
respiratory tract is administered through inhalation of aerosols18.  Another advantage of 
nanoparticles is that they are able to change their surface properties and have large 
surface areas that are not characteristic of other delivery systems.  Nanoparticles are also 
ideal for delivering drugs to a target tumor site for chemotherapy since it can be 
selectively delivered in large quantities to the tumor site while at the same time 
preventing the cause of some of the toxicities seen in solvent-based formulations19.    
Different nanoparticles with various methods of delivery have been used in 
different applications.  One example is the use of nanoparticles for delivering drugs to 
the lungs in the treatment of lung diseases due to the fact that a higher concentration of 
drugs can be delivered and the particles are able to retain in the lungs and have a 
prolonged drug release when nanoparticles are used as a drug carrier.  It was found that 
intravenous injection of the nanoparticles to the lungs was not very effective as most 
accumulated in the reticuloendothelial system, but aerosol delivery would be the best 
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method due to the many advantages5.  Magnetic nanoparticles that are made up of a 
magnetic core (iron oxide, for example) with a biocompatible polymeric outside 
covering (dextran, for example) have also been studied as drug carriers.  These have 
been used to target tumor sites for chemotherapy in which they can be easily retained at 
the desired site with an applied magnetic field20.   
 However, using nanoparticles in conjunction with the drug to be delivered or by 
itself as a drug can have its drawbacks.  Nanoparticles can travel to other sites in the 
body other than its target site and cause adverse side effects in remote organs or tissues5.  
The changing of the physical and chemical properties of these materials may lead to a 
different biological property, which is why the toxicity of nanoparticles is an area of 
study that has been gaining attention17.   
Zinc oxide nanoparticles coated with PVP were used in this study where the 
cytotoxicity of these particles to NIH 3T3 cells is assessed before determining the 
feasibility of its application for use in gene delivery.  PVP is used to prevent aggregation 
of the zinc oxide nanoparticles and zinc oxide was chosen since it is a commonly used 
nanoparticle in personal care products21, 22.  It is proposed by Dr. H. J. Sue’s group 
(Mechanical Engineering, Texas A&M University) that the zinc ions interact with the 
phosphates in the cell culture medium to form zinc phosphate crystals that penetrate cell 
walls and cause the cells to rupture.  The group’s theory is that an increase in the amount 
of PVP used will prevent zinc oxide nanoparticle aggregation, which should result in a 
decrease in cytotoxicity due to the smaller particles formed.  Once the mechanism of cell 
death is understood, the nanoparticles can be modified to be more biocompatible and 
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have less biological side effects for its application in biological systems such as for the 
treatment of prostate cancer.  The assessment of cytotoxicity is done in three parts where 
the metabolic activity, Lactate Dehydrogenase activity (LDH), and amount of DNA 
fragmentation of the cells are quantified along with the observation of cell viability 
under the microscope.  A new control where PVP without nanoparticles was introduced 
in this study to investigate the effects of PVP alone on the cells.  This study is a novel 
approach in studying the cytotoxic effects of zinc oxide nanoparticles on cells with the 
possibility of the presence of phosphates being the reason for the cause of death.    
2.2.1 Materials 
Preliminary assessment of cytotoxicity will be done in four parts where the 
metabolic activity, LDH activity, and amount of DNA fragmentation of the cells are 
quantified along with the observation of cell viability under the microscope.  The assays 
will be carried out after the NIH 3T3 cells have been treated with the various 
nanoparticle concentrations overnight.  The NIH 3T3 cells will be tested with two 
different types of cell culture media: media with phosphates and media without 
phosphates.  A control where PVP without nanoparticles was introduced in this study to 
see the effects PVP alone has on the cells.  This work is a novel approach to determine 
the cytotoxicity of the nanoparticles based on the hypothesis that the presence of 
phosphates played a part in the process.  NIH 3T3 cells were subcultured at 37˚C/5% 
CO2 in DMEM supplemented with 10% DFBS, 1% penicillin streptomycin (PS) 
(Cellgro, Herndon, VA).  PS is added as an antibiotic for the cells to prevent 
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contamination and growth of bacteria in the culture23.  The experiments were conducted 
using cells at passages 5-8.   
2.2.2 Methods 
2.2.2.1 Preparation of Cells 
NIH 3T3 mouse fibroblast cells24 were seeded at a density of 25,000 cells/cm2 in 
a ninety-six well cell culture cluster plate (Costar; Corning, NY) with two different cell 
culture media in a final volume of 50 µL/well.  One set of cells were subcultured at 
37˚C/5% CO2 in DMEM supplemented with 10% DFBS and 1% PS overnight.  The 
other set of cells were subcultured at 37˚C/5% CO2 in DMEM without phosphates 
supplemented with 10% dialyzed DFBS and 1% penicillin streptomycin glutamine 
(PSG) (29.2 mg/mL L-glutamine; Cellgro, Herndon, VA) overnight.  The confluence of 
the cells was checked under the microscope to be at least 90% confluent before carrying 
out the experiment.  
2.2.2.2 Preparation of Nanoparticle Solutions 
Nanoparticle solutions were provided by Dr. H. J. Sue’s group in PVP:ZnO 
concentration ratios of 300:1, 200:1, and 100:1 with a concentration of 0.5 mg/mL ZnO 
dissolved in deionized (DI) water.  ZnO concentrations of 50 µg/mL, 40 µg/mL, 30 
µg/mL, 20 µg/mL, 10 µg/mL, and 5 µg/mL were tested on the cells for each ratio of 
PVP:ZnO.  50 µg/mL and 5 µg/mL of pure PVP (provided by Dr. Mike Bevan’s group) 
dissolved in double DI water were also tested on the cells for each ratio.  For the control, 
no cells were used for the zinc oxide concentrations of 50 µg/mL, 30 µg/mL, and 10 
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µg/mL as well as the 50 µg/mL and 5 µg/mL of pure PVP for each ratio.  The different 
concentrations of zinc oxide solutions were diluted with double DI water and four times 
concentration of media (DMEM + 10% DFBS + 1% PS and DMEM without phosphates 
+ 10% dialyzed DFBS + 1% PSG) to reduce the amount of final volume since no media 
was removed during the experiment to prevent disturbance of the cells.   
2.2.2.3 Cell Metabolic Assay 
120 µL of nanoparticle solution was added to each well with cells.  200 µL of 
nanoparticle solution was added to each control well without cells.  The plates are 
incubated overnight with the nanoparticle solutions.  VybrantTM Cell Metabolic Assay 
Kit (V-23110) (Molecular Probes, Eugene, OR) was used to assess the metabolic activity 
of the cells after twenty-four hours of incubation with the nanoparticles.  This assay 
measures the amount of red-fluorescent resorufin present in the samples, which is the 
resulting product of reduced nonfluorescent resazurin by the enzyme glucose-6-
phosphate dehydrogenase present in viable cells.  50 µL/well of 10µM C12-resazurin 
stock solution was used in the experiment and the plate was incubated with the reagent at 
37˚C/5% CO2 for three hours before making readings.  100 µL was taken from each well 
and the fluorescence at 530 nm absorbance and 590 nm emission was measured with a 
Multi-Detection Microplate Reader with a sensitivity of thirty (BioTek Instruments, 
Winooski, VT).        
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2.2.2.4 Cytotoxicity Detection with Lactate Dehydrogenase (LDH) Activity Assay 
120 µL of each media was used to seed the cells in the initial stage of the 
experiment instead of 50 µL.  The same convention is used here where one set used 
DMEM with phosphates and another set used DMEM without phosphates.  After letting 
the cells grow to confluence overnight, 120 µL of the nanoparticle solution was added to 
each well with cells.  240 µL of nanoparticle solution was added to each control well 
without cells.  In addition to the “low control” where cells received media without 
nanoparticles in the solution there was one more control used for this assay.  A “high 
control” was used where the cells were treated just like the low control but were lysed 
just before the assay for maximum cell death.  LDH is present inside the cell as well as 
in the cytosol, so lysing the cells would allow the maximum amount of LDH measured.  
The amount of cell death was measured with the cytotoxicity detection kitPLUS (LDH) 
(Roche, Mannheim, Germany).  This assay is a non-radioactive colorimetric assay that 
measures the amount of cell death and cell lysis based on the LDH activity released from 
the cytosol of damaged cells.  The reagents were prepared according to the kit and 200 
µL of each sample was taken.  The samples were centrifuged for five minutes to reduce 
the amount of cell debris in the solution and 170 µL of each sample was transferred into 
a new tube.  100 µL of each sample was used for the assay.  The remaining solution was 
stored in -20 oC for the cell death detection ELISA assay.   The samples were incubated 
with the reagent for fifteen minutes before applying the stop solution.  The absorbances 
of the samples were read with a Multi-Detection Microplate Reader at 490 nm 
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immediately after applying the stop solution.  The measured absorbances were plotted 
against the metabolic measurements for viability/cell death comparisons.   
2.2.2.5 Cell Death Detection ELISA Assay         
The amount of cell death was also quantified through the utilization of the Cell 
Death Detection ELISA kit (Roche, Mannheim, Germany).  This kit is a photometric 
enzyme immunoassay that determines the quantitative and qualitative cytoplasmic 
histone-associated DNA fragments after induced cell death.  The absorbances of the 
samples were read with a Multi-Detection Microplate Reader at 405 nm. 
2.2.3 Results 
  It was observed that there is a significant drop in cell viability between 10 and 
20 µg/mL of zinc oxide concentrations for both of the types of cell culture medium used 
in all ratios of ZnO : PVP concentrations.  The results from the VybrantTM Cell 
Metabolic Assay Kit fluorescent readings showed that for both of the cell culture 
medium types the viability of the cells dropped drastically from 10 to 20 µg/mL of zinc 
oxide concentrations.  It can be seen in Figure 5 that the trend is the same in both culture 
types where an increase in zinc oxide concentration showed lower cell viability.  It was 
also noted that there seemed to be a significant difference between the viability of the 
treated cells in media with phosphate and the control whereas minimal difference was 
seen with the treated cells in media without phosphate when compared to the control.   
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(a) 
 
(b) 
Figure 5. Cell Metabolic Assay: (a) DMEM with Phosphate after 3 Hours of Incubation 
with Reagent.  (b) DMEM without Phosphate after 3 Hours of Incubation with Reagent. 
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(a) 
 
(b) 
Figure 6. LDH Assay: (a) DMEM with Phosphate after 15 Minutes of Incubation with 
Reagent.  (b) DMEM without Phosphate after 15 Minutes of Incubation with Reagent. 
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The data also showed that for samples that were treated with just PVP the trend seemed 
to be the opposite where an increase in PVP concentration reduced cell viability while 
for cells treated with nanoparticles it was seen an increase in PVP concentration 
increased cell viability. 
For the LDH assay similar trends were observed in the samples where a 
significant number of cell death was seen between 50 and 20 µg/mL zinc oxide 
concentration.  It can be seen in Figure 6 that a decrease in ZnO : PVP ratio in 
conjunction with a decrease in zinc oxide concentration increases the amount of cell 
death.  The samples from media without phosphate have generally a higher number of 
cell death than samples from media with phosphates.  The effects for 10 and 5 µg/mL 
zinc oxide concentration could not be assessed due to the high numbers from the other 
samples.  The viability/LDH results (Figure 7) showed that 10 µg/mL zinc oxide has a 
higher viability than 5 µg/mL ZnO for all ratios of ZnO to PVP. 
For the cell death detection ELISA (Figure 8) it can be seen that for the samples 
that were in media without phosphate the absorbance was roughly four times as much in 
the higher zinc oxide concentrations than 10 µg/mL, which was also observed in the cell 
metabolic assay (Figure 5).  The samples that were in media with phosphate had 
absorbances that were two times as much in the higher zinc oxide concentrations than 10 
µg/mL, which was observed in the cell metabolic assay as well.  
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(a) 
 
(b) 
Figure 7. Viability/LDH Results of Cell Samples with: (a) DMEM with Phosphate.  (b) 
DMEM without Phosphate. 
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(a) 
  
(b) 
Figure 8.  Cell Death Detection ELISA Assay: (a) DMEM with Phosphate.  (b) DMEM 
without Phosphate. 
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2.3 Efficiency of the Gene Delivery Vehicle 
siRNA is a class of 20-25 nucleotide long double- stranded RNA molecules that 
are involved in the RNA interference (RNAi) pathway by interfering with the expression 
of a specific gene.  The transfection of siRNA in clinical studies have not been 
successful mainly because of several reasons including the lack of an efficient targeted 
delivery, low transfection efficiency, instability to nucleases, poor tissue penetration, and 
nonspecific immune stimulation25.   
 Plasmid DNA is a circular and double-stranded extra-chromosomal DNA 
molecule separate from the chromosomal DNA which is capable of replicating 
independently of the chromosomal DNA.  They range from 1 to over 200 kilobase pairs 
in size and are favorable for gene transfer26.  Plasmid DNA transfection has the same 
efficiency problems seen with siRNA, but their promising results make them a favorable 
method of treatment for certain illnesses. 
 The gene explored in this work is the serum response factor (SRF).  SRF is a 
transcription factor that plays an important part in the development of the embryo.  It has 
been found that SRF is linked to the formation of mesoderm, which is essential for 
embryonic development into a fetus27.  For fully developed mammals, SRF has also been 
found to play a part in the growth of skeletal muscles28.  It is seen for gene transfer of 
both plasmid DNA and siRNA that one of the major problems is the efficiency of the 
procedure.  The genes have to escape from serum nucleases, endosomal entrapment, and 
pass through the nuclear membrane in order to reach the nucleus without damage for 
successful gene transfer29.  The stability of the transferred gene in the nucleus is another 
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problem with gene transfer.  There are viral and non-viral vectors for the delivery of 
genes in gene therapy.  The benefit of non-viral vectors is that they are less 
immunogenic, can be easily produced, and have shown to have better stability.  The 
downside of using non-viral vectors is that they are not as efficient as viral systems.   In 
this work, we used a cationic lipid non-viral system LipofectamineTM 2000 as the vector 
for the delivery of the SRF gene into the cells.  Cationic lipids help with the delivery of 
the gene by forming a compact structure with its negatively charged phosphate backbone 
so it can enter the cell easily30.  In addition to analyzing the samples for the presence of 
SRF, GAPDH will also be analyzed to allow comparison of SRF results.  GAPDH is a 
protein involved in glycolysis and its presence in the extracted samples is usually used as 
an indicator of the quantity of viable cells31.  
2.3.1 Materials 
C3H 10T 1/2 mouse mesenchymal stem cells24 were subcultured at 37˚C/5% CO2 
in Dulbecco’s modification of Eagle’s medium (DMEM with 4.5 g/L glucose, L-
glutamine and sodium pyruvate; Cellgro, Herndon, VA) supplemented with 10% heat 
inactivated fetal bovine serum (DFBS).   
2.3.2 Methods 
2.3.2.1 Maintenance of Cells 
C3H 10T1/2 cells of passage 5-8 were used in the experiments.  The cells were 
expanded and seeded by subculturing at 37˚C/5% CO2 in DMEM supplemented with 
10% DFBS, 1% PS. Twenty-four hours prior to transfection the cell culture media is 
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changed to DMEM supplemented only with 10% DFBS and no antibiotics.  The cells 
were seeded at a density of 25,000 cells/cm2 in a twenty-four well plate (B. D. Falcon, 
Franklin Lakes, NJ) for two-dimensional transfections.     
2.3.2.2 Transfection 
The transfection of SRF plasmid and siRNA were both explored in this study to 
see the effects of both extremes of upregulating and silencing a specific gene.  
Transfection procedure of the plasmid and siRNA were made based on the 
LipofectamineTM 2000 reagent (Invitrogen, Carlsbad, CA) guidelines.   
2.3.2.3 SRF Plasmid DNA 
2.3.2.3.1 Two-Dimensional Environment 
Each well had a final volume of 500 µL.  Plasmid DNA was used at 150 ng/50 
µL Ultraculture medium (Lonza, Walkersville, MD) in each well.  3 µL of 
LipofectamineTM 2000 reagent was mixed with 150 µL of Ultraculture medium.  The 
two solutions were then mixed and let sit at room temperature for twenty minutes.  100 
µL of the mixture was added to each transfected well.  The control wells received 500 
µL of Ultraculture medium.   
2.3.2.3.2 Three-Dimensional Environment    
6,000 molecular weight poly (ethylene glycol) (PEG) gel was dissolved in HBS 
(10 mM HEPES + 150 mM NaCl, pH 7.4) at concentration of 10% (w/v) along with 3.9 
mg/mL of cell adhesive peptide RGDS.  1% (w/v) of acetylphenone was added as a 
28 
 
photoinitiator.  The PEG gel solution was then sterilized through filtration (0.22 µm, 
PVDF; Fisher Brand, Pittsburgh, PA).  C3H 10T1/2 cells were trypsinized and 
resuspended in the sterilized PEG solution.  1 ml of cell suspension was rapidly pipetted 
between two sterile clamped glass plates separated by 0.75 mm spacers and exposed to 
UV light (365 nm, ~ 9 mW/cm2) for 2 min for each side of the gel constructs.  It has 
been shown that the longwave UV light used at similar intensities and exposure times for 
uniform photopolymerization results in minimal cell damage32.  Roughly 7.5 million 
cells were encapsulated in each gel construct.  The prepared hydrogel constructs were 
transferred to a culture plate and incubated at 37˚C/5% CO2 in cell culture media 
(DMEM + 10% DFBS + 1% penicillin streptomycin amphotericin (PSA)).  Change cell 
culture media to pure DMEM the day before transfection to diffuse out antibiotics in the 
gel.   
20 µg of SRF plasmid DNA was dissolved in 500 µL of media and mixed with 
50 µL LipofectamineTM 2000 reagent that was diluted in 500 µL of media.  The gels 
were washed with PBS (HyClone, Logan, UT) for ten minutes before adding the 
transfection solutions.  The transfection solution was then added to 10 mL of media that 
the hydrogel was cultured in and incubated overnight.  The control gel was treated the 
same with the exception of plasmid DNA in the solution.  The media for the transfected 
samples was changed to DMEM with serum and antibiotics after six hours to prevent 
contamination.  
Punch-out samples of the gels were collected after twenty-four hours, forty-eight 
hours, seventy-two hours, and 7 days of incubation with a biopsy punch (6 mm, Miltex, 
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York, PA).  The samples were fast frozen in liquid nitrogen for about two minutes after 
collection and stored in -80 oC until RNA extraction.   
2.3.2.4 SRF siRNA 
2.3.2.4.1 Two-Dimensional Environment 
The final volume was 500 µL in each well.  20 pmol of SRF siRNA + 1 µL of 
LipofectamineTM 2000 reagent were added to each well.  2 µL of SRF siRNA was 
diluted in 50 µL of transfection medium (Santa Cruz Biotechnology, Santa Cruz, CA) 
and mixed gently.  1 µL of LipofectamineTM 2000 reagent was diluted in 50 µL of 
transfection medium, mixed gently, and incubated at room temperature for five minutes.  
The two solutions were combined, mixed gently, and incubated at room temperature for 
twenty minutes.  The cells in the wells were washed once with 2 mL of PBS.  100 µL of 
the transfection mixture was mixed with 400 µL of transfection medium and placed in 
wells for transfection.  Control wells were treated the same with the exception of no 
siRNA in the solution.  The cells were incubated for five-seven hours and media was 
changed to DMEM + 10% DFBS + 1% PSA.  The cells were checked with a confocal 
microscope for fluorescence after twenty-four hours of incubation to see if transfection 
was successful because the control siRNA contains a fluorescent tag.  Pictures of the 
cells were taken. 
2.3.2.4.2 Three-Dimensional Environment 
6,000 molecular weight PEG gel was dissolved in HBS at concentration of 10% 
(w/v) along with 3.9 mg/mL of cell adhesive peptide RGDS.  1% (w/v) of acetylphenone 
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was added as a photoinitiator.  The PEG gel solution was then sterilized through 
filtration.  C3H 10T1/2 cells were trypsinized and resuspended in the sterilized PEG 
solution.  The hydrogels were made in sterile forty-eight well plates by exposure to UV 
light for five minutes.  The gels were made in wells instead of between plates to ensure a 
RNAse free environment.  The hydrogels were then washed with PBS for five minutes 
and then PBS + 1% PSA to prevent possibility of contamination.  The hydrogels were 
transferred to a twenty-four well plate with DMEM + 10% DFBS + 1% PS and 
incubated overnight.  The media was changed to one without antibiotics the day prior to 
transfection.  The same procedure was carried out as in the two – dimensional 
transfection for siRNA. The cells were checked with a confocal microscope for 
fluorescence after twenty-four hours of incubation to see if transfection was successful 
and pictures were taken for all samples.  The hydrogel samples were collected by cutting 
each gel in half and fast frozen in liquid nitrogen for about two minutes and stored in -80 
oC for RNA extraction at a later date.    
2.3.2.5 RNA Extraction 
2.3.2.5.1 Two-Dimensional Environment 
RNeasy® Mini Kit (Qiagen Sciences, Valencia, CA) was used for the extraction 
of RNA from the samples.  70% RNA free ethanol was prepared before the experiment.  
The hood and all equipment are wiped with RNase away to avoid contamination and 
degradation of the RNA in the samples.  The cell culture media was removed and the 
wells were washed with PBS.  1mL/10cm2 Trizol (Invitrogen, Carlsbad, CA) was added 
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to each well and the wells were incubated for five minutes at room temperature.  The 
Trizol extract was transferred to a new tube and 0.2mL chloroform/mL Trizol was added 
to the tubes, shook vigorously for fifteen seconds and incubated at room temperature for 
three minutes.  The samples were centrifuged at 11,000 rpm for fifteen minutes at 4 oC.  
The supernatant was then transferred to a new tube and 1:1 volume of 70% ethanol was 
added and mixed.  The sample was then transferred to an RNeasy column and 
centrifuged at 11,000 rpm at room temperature for fifteen seconds.  700 µL of Buffer 
RW1 was added to the RNeasy column and the column was centrifuged at 11,000 rpm 
for fifteen seconds to wash the column.  The column was then transferred to a new 
collection tube and 500 µL Buffer RPE was added to the RNeasy column.  The column 
was centrifuged for fifteen seconds at 11,000 rpm.  500 µL Buffer RPE was added to the 
column again, but was centrifuged for two minutes instead.  The column was then placed 
in a new collection tube and centrifuged at full speed for one minute.  The column was 
then transferred to a new collection tube and 30 µL of RNase-free water was placed in 
the column to elute the RNA.  The column was centrifuged at 11,000 rpm for fifteen 
seconds and the 30 µL collected was put through the column again to elute the RNA.  
The collected eluted RNA was split into 25 µL and 5 µL quantities and stored in -80 oC 
for later analysis.   
2.3.2.5.2 Three-Dimensional Environment  
500 µL of Trizol reagent was placed into a tube with the samples. Approximately 
1 mL of stainless steel beads were added to the tubes and another 1 mL of Trizol was 
added.  The samples were then homogenized by using a micro beater at 48,000 rpm for 
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10 seconds while keeping the samples on ice for at least thirty seconds afterwards to 
prevent the heating of the samples.  This cycle was repeated nine times until the gels 
were mashed into small pieces.  The solution was then removed from the tubes and 
transferred to a new tube.  The tube was centrifuged at 10,000 rpm for ten minutes at 4 
oC.  The supernatant was transferred into a 2 mL RNase free conical tube and the 
samples were incubated for five minutes at room temperature.  300 µL of chloroform 
was added and the tubes were shook vigorously for fifteen seconds and incubated for 
three minutes at room temperature.  The tubes were then centrifuged at 10,000 rpm for 
fifteen minutes at 4 oC.  The supernatant was transferred into new conical tubes and add 
1 µL of 4 µg/µL glycogen for each 10 µL RNA sample.  10 µL was used due to the large 
volume.  750 µL of isopropanol was added and mixed.  The sample was incubated at -20 
oC for an hour and a half.          
2.3.2.5.2.1 Cleaning RNA 
Centrifuge samples at 10,000 rpm at 4 oC for twenty minutes.  The supernatant 
was discarded without disturbing the pellet and 1.5 mL of 75% RNase free ethanol was 
added.  The samples were centrifuged at 8,000 rpm at 4 oC for ten minutes.  The 
supernatant was discarded without disturbing the pellet and 1.5 mL of 95% RNase free 
ethanol was added.  The samples were centrifuged at 8,000 rpm at 4 oC for ten minutes.  
The supernatant was discarded without disturbing the pellet and let dry for ten minutes at 
room temperature.   
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2.3.2.5.2.2 DNase Treatment 
The pellet was resuspended in 87.5 µL of RNase free water, 10 µL of RDD 
buffer, and 2.5 µL of DNase I.  The samples were incubated at 37 oC for thirty minutes 
and then transferred to a 70 oC oven for five minutes to inactive the enzyme and 
immediately chilled on ice.  10 µL of 3M NaAc at pH 5.5 was added.  275 µL of 100% 
RNA free ethanol was then added and incubated overnight at -20 oC. 
2.3.2.5.2.3 Second Precipitation 
The samples were centrifuged at 10,000 rpm for twenty-five minutes at 4 oC.  
The supernatant was removed without disturbing the pellet.  500 µL of 75% RNase free 
ethanol was added and centrifuged at 8,000 rpm for ten minutes at 4 oC.  The supernatant 
was discarded without disturbing the pellet.  500 µL of 95% RNase free ethanol was 
added and centrifuged at 8,000 rpm for ten minutes at 4 oC.  The supernatant was 
discarded without disturbing the pellet and let dry for ten minutes at room temperature.  
The pellet was dissolved in 30 µL of RNase free water and stored in -80 oC if not 
running RT-PCR immediately.   
2.3.2.5.2.4 Protein Dialysis 
450 µL of ethanol was added to each tube containing protein stored from earlier.  
Each tube was mixed gently by inversion.  The DNA pellet was collected by 
centrifuging at 2,000 Xg for ten minutes at 4 oC.  The samples were dialyzed with 0.1% 
SDS buffer at 4 oC over a period of two days with a change of buffer after one day.  
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Snake Skin® Pleated Dialysis Tubing (3,500 MW, Thermo Fisher Scientific, Rockford, 
IL) was used as the membrane for the dialysis.   
2.3.2.6 RNA Quantification 
Quant-iTTM RNA Assay Kit (Invitrogen, Eugene, OR) was used to quantify the 
RNA concentration extracted from the samples.  The working solution was diluted 1:200 
and 200 µL was added to each well for each sample.  10 µL of each standard (0 ng and 
100 ng) were added to the wells with working solution and 5 µL of the RNA samples 
were added to the wells with working solution.  The fluorescence at 644/673 nm were 
read at a sensitivity of twelve with a Spectra Max Gemini EM Spectrofluorometer 
(Molecular Devices, Union City, CA).   
2.3.2.7 RT-PCR 
SuperScriptTM III Platinum® SYBR® Green One-Step qPCR System (Invitrogen, 
Eugene, OR) was used to carry out the RT-PCR in order to compare and quantify the 
RNA in the samples.  Duplicates were made for each sample because both GAPDH 
(human glyceraldehydes-3-phosphate dehydrogenase) and SRF genes are amplified.  
Samples were prepared and loaded into the Applied Biosystems StepOneTM Real-Time 
PCR machine (Applied Biosystems, Foster City, CA).  A comparative CT was made for 
the RT-PCR samples.  This quantitation method determines the relative target quantity in 
samples.  The SYBR® Green 1 dye used is a fluorescent-based reagent that generates a 
fluorescence signal when bound to double-stranded DNA, which will then allow the 
quantification of PCR products through the cycles33.      
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2.3.2.8 Protein Quantification 
Coomassie (Bradford) Protein Assay Kit (Thermo Fisher Scientific, Rockford, 
IL) was used to quantify the amount of protein in the samples.  5 µL of each standard 
and sample were added to 250 µL of Coomassie Reagent.  The absorbance was 
measured at 595 nm with a Multi-Detection Microplate Reader.   
2.3.2.9 Western Blot 
10% of 6 mL of the resolving gel for Tris-glycine SDS-polyacrylamide and 3 mL 
of 5% of the stacking gel were used for gel electrophoresis.  The samples were prepared 
by adding 5X sample buffer and diluting it to 1X with the samples, and boiled in water 
for ten minutes.  5 µL of stain marker was loaded on the side.  SDS-PAGE 
electrophoresis running buffer was used and the gel was ran at 100 volts for twenty 
minutes and then 180 volts for one hour.   The gel was removed from the cassette and 
the samples were transferred onto a membrane for Western Blotting.  The pads, filter 
paper, and membrane were soaked in the transfer buffer before assembling.  1 X Novex® 
Tris-Glycine transfer buffer was used.  The materials were stacked with two blotting 
pads on the bottom, a filter paper, gel, transfer membrane, filter paper, and three blotting 
pads on top.  The transfer was run at twenty-five volts for an hour and a half.  The 
membrane was then washed with double DI water for five minutes twice on a rotary 
shaker.  The membrane was soaked in blocking solution 3% BSA for sixty minutes on a 
rotary shaker.  The membrane was rinsed with TBST for ten minutes.   The membrane 
was cut in half between 55and 43 kDa according to the ladder (GAPHD is around 36 
kDa and SRF is around 51 kDa31) and was incubated overnight in primary antibody 
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solution (1:200 SRF and 1:200 GAPDH, Santa Cruz Biotechnology, Santa Cruz, CA) at 
4 oC.  The top half of the membrane was incubated with SRF primary antibody and the 
bottom half of the membrane was incubated with GAPDH primary antibody.   
The membrane was washed for ten minutes with TBST and repeated twice.  The 
membrane was then incubated at room temperature with the secondary antibody 
solutions (1:10,000 anti-mouse HRP for GAPDH and 1:10,000 anti-rabbit HRP for SRF, 
Santa Cruz Biotechnology, Santa Cruz, CA) for sixty minutes.  The membrane was 
washed with TBST for ten minutes and repeated twice.  The membrane was washed with 
TBS for ten minutes and repeated once.  The membrane was then placed on a sheet of 
transparent plastic and a mixture of Western Blotting Luminol Reagent (Santa Cruz 
Biotechnology, Santa Cruz, CA) was applied to the surface.  The reaction was allowed to 
develop for a minute and another sheet of transparent plastic was placed on top.  The 
membrane was exposed to the film for four minutes in the dark room.  The film was 
immersed in the developer solution for about one minute and washed in double DI water 
for about one minute and soaked in the fixer solution for two minutes with shaking.  The 
film was then washed with double DI water and air dried.     
2.3.2.10 Gel Electrophoresis of RT-PCR Samples 
 35 mL of 2% agarose gel was prepared for the gel electrophoresis.  The agarose 
powder was dissolved in 35 mL of 1X TAE buffer in a beaker, which was covered with 
a paper towel and secured with a rubber band.  The beaker was placed in a microwave 
and heated for ten seconds.  This was repeated three times with shaking and mixing of 
the beaker after each time.  The mixture was let cool at room temperature and then 
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poured into the mold with an appropriate comb.  After thirty minutes the mold was 
placed in an electrophoresis cartridge and filled with buffer solution.  The wells were 
loaded with 5 µL of markers and 12µL of each sample (2 µL loading buffer + 10 µL 
sample).  The gel was run at 100 volts for approximately forty-two minutes.  The gel 
was then placed in ethidium bromide solution for forty minutes with rocking.  The gel 
was washed with buffer for ten minutes with rocking before imaging. 
 The gel was then imaged with the Versa Doc imager machine (Bio-Rad, 
Hercules, CA) and a photo was taken. 
2.3.3 Results 
2.3.3.1 Two-Dimensional Environment 
The cells were observed twenty-four hours after transfection and were found to 
fluoresce under the microscope with siRNA, which suggested the transfection was 
successful (Figures 9 and 10). 
The mRNA extracted and purified from the SRF plasmid DNA transfection 
experiment was quantified and the results are presented in Table 2 in the Appendix.  
This shows an increase in amount of mRNA produced as time is increased, which 
suggests an increase in the number of cells and viability.  The proteins collected from the 
SRF plasmid DNA transfection samples were analyzed with a Western Blot to see if the 
transfection was successful by comparing the expressions and the picture is shown as 
Figure 11.   
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Figure 9. C3H 10T1/2 Cells 24 Hours after Transfection (Brightfield). 
 
 
 
Figure 10. C3H 10T1/2 Cells 24 Hours after Transfection (FITC). 
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Figure 11.  Photo of Western Blot of Protein Phases from 2-D Transfection. 
 
 
It can be seen from the Western Blot that there is an amplified expression of 
GAPDH with the increase of time, which suggests an increase in cell number and 
viability that is seen as the amount of time the cells are incubated is increased.  The 
expression of SRF is generally higher in the transfected sample than in the control, 
which suggests that the transfection was successful.  The control SRF expression is also 
observed to increase with time, which also suggests an increase in cell number and 
viability as length of time increases.  It is also observed that the amplified expression of 
SRF in transfected samples decreased through time, which is expected as the inserted 
gene is not very stable and will be expelled from the cell through time. 
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 The mRNA extracted and purified from the SRF siRNA transfection experiment 
was quantified and the results are presented in Tables 3 and 4 in the Appendix.  It was 
observed that the control wells appear to have been contaminated, which resulted in the 
very low mRNA quantification reading for the forty-eight hour control sample.  The 
other samples seem to have a good amount of RNA present with an increase in the 
amount of RNA for the forty-eight hour sample, which confirms an increase in the 
amount of cells with time. 
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Figure 12. 2-D siRNA Transfection Relative SRF Expression after 24 Hours. 
 
 
  Initial analysis of the CT from RT-PCR results from the siRNA transfection 
after twenty-four hours is presented in Figure 12.  There is a 55% decrease in SRF 
expression in the transfected cells, but a decrease around 70% was expected for the time 
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period34, which means fine tuning of the transfection procedure is needed.Due to a 
contamination in the control sample for the transfection and limited time to repeat the 
experiment, the data collected from the RT-PCR results could not be used to analyze the 
effects of forty-eight hours after transfection.  An electrophoresis agarose gel of the RT-
PCR samples for twenty-four hours after transfection showed clean bands for SRF and 
GAPDH in the samples (Figure 13), which confirmed the products from the RT-PCR.  
However, an electrophoresis agarose gel of the RT-PCR samples for forty-eight hours 
after transfection did not show clean distinct bands of SRF and GAPDH in the samples 
as seen in the previous gel (Figure 14), which was reflected in the RT-PCR results and is 
due to the contamination in the control sample.   
 
Figure 13. Gel Electrophoresis of RT-PCR Results for 24 Hrs after Transfection. 
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Figure 14. Gel Electrophoresis of RT-PCR Results for 48 Hrs after Transfection. 
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2.3.3.2 Three-Dimensional Environment 
The cells were observed through the microscope twenty-four hours after 
transfection and were found to show no fluorescence for the siRNA, which suggested the 
transfection was not successful.  However, analysis of the extracted mRNA showed that 
transfection was successful. 
The mRNA extracted and purified from the SRF plasmid DNA transfection 
experiment was quantified and the results are presented in Table 5 in the Appendix.  RT-
PCR results were promising even though the amount of SRF expression was observed to 
be down 4.4% compared to the control after twenty-four hours but was up 12.11% after 
168 hours, which suggest the transfection was fairly successful since an increase in SRF 
expression was still observed after seven days (Figure 15).  Only the samples from 
twenty-four hours and seven days were analyzed in order to analyze both the short-term 
and long-term effects of the transfection. 
The mRNA extracted and purified from the SRF siRNA transfection experiment 
was quantified and the results are presented in Table 6 in the Appendix.  RT-PCR results 
also did not yield very good results where no data was obtained from the control samples 
and only three amplifications values were obtained for the transfected samples for after 
twenty-four hours of transfection, which cannot be used for analysis due to lack of data.  
The RT-PCR transfection data from forty-eight hours show that there is a 1.3% 
reduction in the expression of SRF compared to the control (Figure 16).  This means that 
either the siRNA was successfully transfected in the cells but were already degraded by 
forty-eight hours or that the transfection was not successful at all.   
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Figure 15. 3-D Plasmid DNA Transfection Relative SRF Expression after  
24 and 168 Hours. 
 
 
 
 
Figure 16. 3-D siRNA Transfection Relative SRF Expression after 48 Hours. 
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It was seen that there is a minimal amount of RNA extracted compared to the 
standards and the Western blots showed little or no bands.  The experiment was repeated 
with a second set of treatments where the transfection media was not changed after six 
hours of incubation in order to observe the effects of a longer transfection period.   
The results from the Western blot from the three-dimensional transfection show 
that there seems to be a higher concentration of SRF present in the sample that media 
was not changed after transfection (Figure 17).  GAPDH bands were not visible in the 
Western blot and different antibodies will be used in the future.  Due to the lack of 
GAPDH data we could not normalize the SRF expression and normalized the data with 
each other with the Scion Image program.  After normalizing the data and analyzing the 
bands it was found that there is a significant decrease in SRF expression between the 
transfected sample and the control where the media was not changed after twenty-four 
hours (Figure 18)35.  It was also seen that there was little difference between the control 
and transfected in the forty-eight hour sample, which could be due to the decrease in cell 
viability for being in the gel and the increase in SRF production by the cells through 
time after siRNA is degraded.  This information tells us that the effective time frame for 
this transfection method would be between twenty-four and forty-eight hours.   
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Figure 17. Photo of Western Blot of Protein Phases from 3-D Transfection (SRF Half). 
 
 
 
 
Figure 18. Western Blot Quantification Results from 3-D Transfection. 
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3. DISCUSSION 
Novel and efficient drug delivery methods are currently being explored as 
alternative ways to administer treatment for a wide range of patients with different 
conditions.  Certain delivery methods are more favorable than others due to the nature of 
the drug and the location of its target site.  Aspects of a controlled release gene delivery 
system from an implantable device were explored in this work.  It was seen that the 
degradation times for the same polymer concentration vary from time to time and is not 
consistent.  This is one of the challenges when finding a suitable polymer material for a 
timed-release drug delivery module.  In this work, we hypothesized that 50/50 DLG 5A 
would have the longest degradation time, but it was observed to have degraded within 
the first few days of several experiments.  The next polymers to have a longer 
degradation time should be 50/50 DLG 4A, 50/50 DLG 2.5A, 65/35 DL 3A, 75/25 DLG 
2A, 85/15 DLG 1A, and finally 75/25 DLG 1A according to their properties.  However, 
this was not observed in the several experiments we carried out for all seven polymer 
compositions made the same way at the same time.  Instead, 65/35 DL 3A and 50/50 
DLG 4A were the two compositions that had a degradation time of around two weeks.  
This could be largely due to the difficulty of maintaining a consistent thickness in the 
polymer membrane created.  It was also observed by Grayson et al12 that certain polymer 
compositions did not exhibit expected behavior during her work.   
The results presented here show that for zinc oxide nanoparticles with a PVP 
coated layer the cytotoxicity increases as the concentration of zinc oxide increases and 
that the presence of PVP may play a role in the cytotoxic effects.  The significant 
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decrease in cell viability between 10 and 20 µg/mL could be due to the covering of cells 
by the nanoparticles, thus, impeding the ability for nutrients to reach the cells on the 
bottom of the wells, which was also observed in previous studies36.  It was also shown 
that the method of cell death is very likely through apoptosis since it is a programmed 
cell death that results in the fragmentation of DNA37, which was observed that a high 
level of low cell viability is associated with a high level of DNA fragmentation.  It is 
unlikely for apoptosis to take place if the cell walls were punctured and ruptured since 
apoptosis takes time to carry out since it is a programmed cell death.  These findings do 
not support the theory that an increase in PVP causes an increase in the number of cell 
death through the interactions between the zinc oxide particles and phosphate 
moleculeus to create zinc phosphate crystals that puncture cell walls.  
Also presented in this work is the feasibility of the gene transfection of SRF 
plasmid DNA and siRNA with a lipid-based non-viral vector.  It was found that the 
transfection of the plasmid DNA and siRNA was semi-successful in the three-
dimensional environment and fairly successful in the two-dimensional environment.  
This could be due to the transfection method used in the experiments where a lipid 
vector was used, which reduced the transfection efficiency30.  In order for the gene to be 
transfected into the cell in a three-dimensional environment the liposome encapsulated 
gene has to be able to reach the cells to fuse with the cell wall and transport the gene into 
the nucleus (Figure 2), but because the cells were encapsulated in a PEG gel construct it 
was difficult for the liposomes to be able to come in contact with most of the cells, thus, 
reducing the efficiency of the transfection.  However, it was found that the transfection 
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of the siRNA of SRF was fairly successful in the three-dimensional environment within 
a twenty-four to forty-eight hour time frame, and this information allows us to see that 
the LipofectamineTM 2000 transfection method is feasible with the siRNA in the three-
dimensional environment within the time frame.
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4. CONCLUSION AND FUTURE RESEARCH 
The aim of this study was to explore three key aspects of gene therapy for its 
application in tissue engineering.  It is important to be able to control the release of the 
drugs within the body so that optimal therapeutic levels can be obtained.  It is also 
important to assess the cytotoxicity of any materials used in conjunction with the 
delivered gene to understand the interaction of the materials and the surrounding tissues 
and organs to prevent adverse side effects.  Lastly, it is important to investigate the 
efficacy of the delivery system designed to assess the feasibility of taking the method to 
the next level.   
Designing a biodegradable timed-release microchip with multiple wells for 
loading drugs is ideal for certain applications, but finding an appropriate polymer 
composition to achieve a certain degradation time and maintain a constant membrane 
thickness for the situation is difficult.  12% 50/50 DLG 4A and 65/35 DL 3A can be 
tested with drugs to observe the release rates.  Other formulations than the ones tested 
could also be explored. 
The cytotoxicity of the zinc oxide nanoparticles is significant at higher 
concentrations of the nanoparticles and lower concentrations of PVP, which gives us 
valuable information regarding the threshold concentration of zinc oxide that should be 
used when using them as an aid in delivering the genes to their target sites. 
The concept of gene therapy is in its initial stages and has not yet been proven to 
be an effective method of treating a variety of illnesses and diseases.  It was seen in this 
work that it is difficult to transfect the plasmid DNA or siRNA in a three-dimensional 
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environment especially when the inserted gene is usually rejected within a short time 
period (within twenty-four hours).  The effects of the inserted gene would be short and it 
was observed to be somewhere between twenty-four and forty-eight hours as the optimal 
therapeutic time frame.  Alternative methods of transfection that could be considered 
would be to use viral vectors instead of non-viral vectors to increase efficiency.   
 These findings and results from the above proposed research will benefit the 
continual search for a better gene therapy drug delivery method as well as currently 
explored methods.   
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RT-PCR results from 24 hours after 2-D transfection of siRNA 
 CONTROL TRANSFECTED 
 GAPDH GAPDH SRF SRF GAPDH GAPDH SRF SRF 
CT 20.87 20.37 26.69 25.59 17.25 16.95 23.94 23.63 
Mean CT  
 20.62  26.14  17.1  23.785 
∆ CTa 
   5.52    6.685 
∆ ∆ CTb 
   0    1.165 
2 - ∆ ∆ CT 
   1    0.445964 
a 
∆ CT = CT SRF- CT GAPDH. 
b 
∆ ∆ CT =  ∆ CT SRF- ∆ CTSample 
 
RT-PCR results from 48 hours after 2-D transfection of siRNA 
 CONTROL TRANSFECTED 
 GAPDH GAPDH SRF SRF GAPDH GAPDH SRF SRF 
CT 33.62  34.95 36.95 23.97  24.32 23.96 
Mean CT  
 33.62  35.95  23.97  24.14 
∆ CT 
   2.33    0.17 
∆ ∆ CT 
   0    -2.16 
2 - ∆ ∆ CT 
   1    4.469149 
 
 
RT-PCR results from 24 hours after 3-D transfection of plasmid DNA 
 CONTROL TRANSFECTED 
 GAPDH GAPDH SRF SRF GAPDH GAPDH SRF SRF 
CT 22.43 22.69 29.54 29.96 21.92 21.94 28.91 29.46 
Mean CT  
 22.56  29.75  21.93  29.185 
∆ CT 
   7.19    7.255 
∆ ∆ CT 
   0    0.065 
2 - ∆ ∆ CT 
   1    0.955945 
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RT-PCR results from 168 hours after 3-D transfection of plasmid DNA 
 CONTROL TRANSFECTED 
 GAPDH GAPDH SRF SRF GAPDH GAPDH SRF SRF 
CT 25.91 25.78 31.36 31.95 26.31 26.79 32 32.39 
Mean CT  
 25.845  31.655  26.55  32.195 
∆ CT 
   5.81    5.645 
∆ ∆ CT 
   0    -0.165 
2 - ∆ ∆ CT 
   1    1.121166 
 
RT-PCR results from 48 hours after 3-D transfection of siRNA (no media change) 
 CONTROL TRANSFECTED 
 GAPDH GAPDH SRF SRF GAPDH GAPDH SRF SRF 
CT 29.19 28.94 33.86 34.94 29.49 29.17 34.8 34.57 
Mean CT   29.065  34.4  29.33  34.685 
∆ CT    5.335    5.355 
∆ ∆ CT    0    0.02 
2 - ∆ ∆ CT    1    0.986233 
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Table 2.  RNA Quantification for 2-D Transfection of SRF Plasmid DNA 
 
Control 
24 hrs 
Transfected 
24 hrs 
Control 
48 hrs 
Transfected 
48 hrs 
Control 
72 hrs 
Transfected 
72 hrs 
Reading 1756.3 1638.6 3662.2 3497.2 5973.4 6175.3 
 
Table 3. RNA Quantification for 2-D Transfection of SRF siRNA after 24 Hrs 
 Control 24 hrs Transfected 24 hrs 
Reading 499.14 878.97 
 
Table 4. RNA Quantification for 2-D Transfection of SRF siRNA after 48 Hrs 
  Control 48 hrs Transfected 48 hrs 
Reading 79.132 948.54 
 
Table 5.  RNA Quantification for 3-D Transfection of SRF Plasmid DNA 
  
Control 
24 hrs 
Transfected 
24 hrs 
Control 
168 hrs 
Transfected 
168 hrs 
Reading 185.083 204.954 123.967 113.556 
 
Table 6. RNA Quantification for 3-D Transfection of SRF siRNA after 24 Hrs 
 
Control 
24 hrs 
Transfected 
24 hrs 
Control 
24 hrs no 
change 
Transfected 
24 hrs no 
change 
Reading 88.089 84.99 80.93 81.803 
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